Maha Katabi combines a PhD in Pharmacology from McGill with CFA credentials and previously built crossover investing platforms that invested across both public and private biotech companies before joining Sofinnova in 2019. She focuses on clinical-stage assets and single-asset companies in complex areas like radiopharmaceuticals and targeted oncology, while also serving as an ecosystem builder through roles like chairing Exactis Innovation, a precision oncology network that provides real-world evidence data to researchers.